The Human Skin Blanching Assay for Topical Corticosteroid Bioavailability Assessment

  • Eric W. Smith
  • Eric Meyer
  • John M. Haigh
Chapter

Abstract

The human skin blanching assay (often called the vasoconstrictor assay) has been used for nearly 30 years as a means of qualitatively assessing the topical availability and potency of corticosteroids. This bioassay uses the skin-whitening side effect of this class of drugs to estimate the rate and extent of corticosteroid diffusion to the dermal vasculature, the intensity of this whiteness correlating directly with the topical availability of the drug. This versatile bioassay may be applied in a number of test modes: to evaluate the topical potency of newly synthesized corticosteroid molecules, to assess the effects of the delivery vehicle formulation on the delivery of the drug to the skin, to assess the efficacy of penetration enhancers, or to rank the potency of commercial formulations for clinical and registration purposes. The latter has probably been the most widespread use of the assay, as it is now well established that incorporating identical concentrations of the same drug into two different topical vehicles (chemical equivalency) does not necessarily produce topically bioequivalent dosage forms. Various forms of the blanching assay have been used to compare drug release from ointments,1,2 creams, and gels,2,3 and for the comparison of generic formulations to trade-name “equivalents.”4–6 The major problem that arises with this data is that the diversity in experimental methodology practiced by the various researchers7–9 makes interstudy comparison of results difficult.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Barry BW, Woodford R. Comparative bio-availability and activity of proprietary topical corticosteroid preparations: vasoconstrictor assays on thirty-one ointments. Br J Dermatol. 1975;93: 563–571.PubMedCrossRefGoogle Scholar
  2. 2.
    Barry BW. Bioavailability of topical steroids. Dermatologica. 1976;152:47–65.PubMedCrossRefGoogle Scholar
  3. 3.
    Barry BW, Woodford R. Comparative bio-availability of proprietary topical corticosteroid preparations; vasoconstrictor assays on thirty creams and gels. Br J Dermatol. 1974;91:323–338.PubMedCrossRefGoogle Scholar
  4. 4.
    Stoughton RB. Are generic formulations equivalent to trade name topical glucocorticoids? Arch Dermatol. 1987;123:1312–1314.PubMedCrossRefGoogle Scholar
  5. 5.
    Jackson DB, Thompson C, McCormack JR, et al. Bioequivalence (bioavailability) of generic topical corticosteroids. J Am Acad Dermatol. 1989;20:791–796.PubMedCrossRefGoogle Scholar
  6. 6.
    Olsen EA. A double-blind controlled comparison of generic and trade-name topical steroids using the vasoconstriction assay. Arch Dermatol. 1991;127:197–201.PubMedCrossRefGoogle Scholar
  7. 7.
    McKenzie AW, Stoughton RB. Method for comparing the percutaneous absorption of steroids. Arch Dermatol 1962;86:608–610.CrossRefGoogle Scholar
  8. 8.
    Falconi G, Rossi GL. Paper-patch test for evaluating vasoconstrictive activity of corticosteroids. Arch Dermatol. 1972;105:856–858.PubMedCrossRefGoogle Scholar
  9. 9.
    Place VA, Velazquez JG, Burdick KH. Precise evaluation of topically applied corticosteroid potency. Modification of the Stoughton-McKenzie assay. Arch Dermatol. 1970;101:531–537.PubMedCrossRefGoogle Scholar
  10. 10.
    Haigh JM, Kanfer I. Assessment of topical corticosteroid preparations: the human skin blanching assay. Int J Pharm. 1984;19:245–262.CrossRefGoogle Scholar
  11. 11.
    Smith EW, Meyer E, Haigh JM, et al. The human skin blanching assay as an indicator of topical corticosteroid bioavailability and potency: an update. In: Bronaugh RL, Maibach HI, eds. Percutaneous Absorption. Vol. 2. New York: Marcel Dekker; 1989:443.Google Scholar
  12. 12.
    Haigh JM, Smith EW. Topical corticosteroid-induced skin blanching measurement: eye or instrument? Arch Dermatol. 1991;127:1065.PubMedCrossRefGoogle Scholar
  13. 13.
    Cornell R, Stoughton RB. Correlation of the vasoconstriction assay and clinical activity in psoriasis. Arch Dermatol. 1985;121:63–67.PubMedCrossRefGoogle Scholar
  14. 14.
    Gibson JR. Predicting the topical potency of topical corticosteroids. Clin Exper Dermatol. 1985; 10: 403–404.CrossRefGoogle Scholar
  15. 15.
    Burdick KH. Various vagaries of vasoconstriction. Arch Dermatol. 1974;110:238–242.PubMedCrossRefGoogle Scholar
  16. 16.
    Haigh JM, Kanfer I, Meyer E, et al. Relative potencies of topical corticosteroid formulations. Br J Dermatol. 1985;113:502–503.PubMedCrossRefGoogle Scholar
  17. 17.
    Raymond GP, Collins JP, Mailhot R. Triple corticosteroid integrated system in the treatment of psoriasis: a new approach to topical corticosteroid therapy. Curr Ther Res 1985;37:770–778.Google Scholar
  18. 18.
    Shah V, Peck CC, Skelly JP. “Vasoconstriction”—skin blanching assay for glucocorticoids—a critique. Arch Dermatol. 1989;125:1558–1561.PubMedCrossRefGoogle Scholar
  19. 19.
    Conner DP, Zamani K, Nix D, et al. Use of reflectance spectrometry in the corticosteroid skin blanching assay. Clin Pharmacol Ther. 1990;47:170.Google Scholar
  20. 20.
    Trikam DSK, Morton DJ. Development of an objective method for assessing topical corticosteroid efficacy. Cent African J Med. 1985;31:228–229.Google Scholar
  21. 21.
    Aiache J-M, Lafaye C, Bouzat J, et al. Évaluation de la disponibilité topique des corticoïdes par thermographie. J Pharm Belg. 1980;35:187–195.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • Eric W. Smith
    • 1
  • Eric Meyer
    • 2
  • John M. Haigh
    • 1
  1. 1.School of Pharmaceutical SciencesRhodes UniversityGrahamstownSouth Africa
  2. 2.Pharmacy DepartmentThe University of SydneySydneyAustralia

Personalised recommendations